Patients with atopic dermatitis (AD) are significantly burdened with unpleasant and often embarrassing symptoms of the condition. Such a burden confirmed a need for effective therapies.
In a study, when dosed at 300mg, dupilumab showed a significant improvement in patient-reported outcomes for individuals with moderate-to-severe AD.